[Skip to Content]
[Skip to Content Landing]
Research Letter
September 2018

Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial

Author Affiliations
  • 1Department of Medicine, University of Illinois at Chicago
  • 2Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago
  • 3Department of Radiation Oncology, University of Illinois at Chicago
  • 4Department of Radiology, University of Illinois at Chicago
  • 5School of Public Health, Division of Epidemiology and Biostatistics, University of Illinois at Chicago
  • 6University of Illinois Cancer Center, Chicago
  • 7Division of Hematology/Oncology, University of Illinois at Chicago
JAMA Oncol. 2018;4(9):1291-1293. doi:10.1001/jamaoncol.2018.2823

The National Lung Screening Trial (NLST) showed a 20% reduction in lung cancer (LC) mortality by detection of LC at an early stage with low-dose computed tomography (LDCT) scanning vs chest radiography for individuals who are at high-risk for LC based largely on age and smoking history.1 A total of 90.9% of the NLST participants were white, and only 4.5% were African American. Yet, although the overall incidence and mortality from LC have been declining in the United States, African Americans have the highest LC mortality rate compared with other races. The magnitude of this racial disparity has increased over the past 4 decades.2 Screening programs tailored to high-risk patients of minority races/ethnicities could help to reduce this health disparity and save even more lives.3 The goal of this study was to assess the demographic characteristics, baseline LDCT scan findings (lung reporting and data system, Lung-RADS4), and detected LCs in an inner city, minority-based population at the University of Illinois at Chicago (UIC) that included federally qualified health centers vs that of the NLST.